AUS
NZ
UK
CA
USA
IND
Lumos Diagnostics Holdings Limited (ASX:LDX), a Melbourne-based company specialising in point-of-care diagnostic technology, announced on 28 July 2026 the issuance of 431,229 fully paid ordinary shares after employee stock options were exercised. The shares were issued through a mix of cash exercises and cashless option conversions. To facilitate on-market sales of these shares without additional disclosure, the company has provided a Section 708A cleansing statement. This announcement confirms Lumos Diagnostics remains compliant with its continuous disclosure obligations to the ASX.
Key Points
- Lumos Diagnostics Holdings Limited (ASX:LDX) focuses on rapid, cost-effective point-of-care diagnostic tests and digital reader platforms.
- The company issued 36,821 shares via cash exercise of unquoted options at $0.0576 per share and 394,408 shares through cashless employee option exercises.
- Total shares issued from employee option exercises amount to 431,229 fully paid ordinary shares.
- The 2026 Annual Report will be released on or before 31 August 2026 and contains no excluded information requiring disclosure under the Corporations Act.
Details of Employee Option Exercises and Share Issuance
Lumos Diagnostics completed issuing 431,229 fully paid ordinary shares through two employee option exercise methods. The first tranche involved 36,821 shares issued upon cash exercise of unquoted options held by an employee at an exercise price of $0.0576 per share, reflecting employee confidence and direct capital contribution. The second tranche comprised 394,408 shares issued via cashless exercise of unquoted employee options, allowing option holders to realise in-the-money value without upfront cash payment.
This share issuance was conducted without disclosure under Part 6D.2 of the Corporations Act, which permits certain issuances outside the usual disclosure framework. To comply and enable unrestricted on-market trading, Lumos Diagnostics issued a Section 708A(5)(e) cleansing statement under the Corporations Act 2001 (Cth). This notice confirms the company meets all conditions allowing holders of the newly issued shares to sell them on-market without triggering further disclosure. This activity represents routine share capital management related to employee equity incentive exercises.
Lumos Diagnostics’ Business Model and Diagnostic Technology
Specialising in rapid, cost-effective point-of-care diagnostic tests, Lumos Diagnostics develops and commercialises technologies to assist healthcare professionals in accurate diagnosis and management of medical conditions. The company operates three key revenue streams: customised assay development for clients, manufacturing services for point-of-care tests, and proprietary Lumos-branded diagnostic test development, manufacturing, and commercialisation. Their diagnostic portfolio targets infectious and inflammatory diseases, addressing significant global healthcare needs.
A key competitive advantage is Lumos Diagnostics’ proprietary digital reader platforms that improve the accuracy and usability of point-of-care tests. Headquartered in Melbourne, Victoria, the company operates under the Lumos Diagnostics and Febridx brands. The point-of-care diagnostics market is a major healthcare segment driven by the demand for rapid, accurate, and affordable diagnostic solutions in both clinical and non-clinical settings. Lumos’ dual focus on customised services and proprietary products positions it to capture value across multiple global diagnostics market segments.
Compliance with Regulatory and Continuous Disclosure Requirements
Lumos Diagnostics confirmed compliance with all relevant provisions of Chapter 2M of the Corporations Act, which governs continuous disclosure for ASX-listed entities. The company also affirmed adherence to Section 674 of the Corporations Act, which imposes additional disclosure obligations. This confirmation indicates that the share issuance does not deviate from the company’s ongoing compliance with Australian securities laws and ASX listing rules.
The company will release its annual report and financial statements for the year ended 30 June 2026 on or before 31 August 2026. The draft 2026 Annual Report contains no excluded information as defined by Sections 708A(7) and 708A(8) of the Corporations Act that would require disclosure in connection with the cleansing notice. Excluded information typically includes material adverse information impacting the company’s securities price or investor decisions. The absence of such information suggests no material adverse developments affecting the company’s financial position or trading performance as of the reporting date.
Section 708A Cleansing Statement and Market Trading Implications
The Section 708A(5)(e) cleansing statement issued by Lumos Diagnostics provides legal certainty for holders of the newly issued shares to sell these securities on-market. Under Australian securities law, shares issued without disclosure documentation cannot generally be traded on-market unless a cleansing notice is provided confirming the company’s disclosing entity status and absence of excluded information. This cleansing statement removes legal barriers, enabling employee option holders to realise value through unrestricted market sales.
This mechanism is standard in Australian corporate law to facilitate equity compensation while protecting investors. The company’s confirmation of compliance with continuous disclosure requirements ensures all material information has been disclosed prior to permitting unrestricted trading. This announcement highlights Lumos Diagnostics’ commitment to corporate governance and regulatory compliance in managing equity incentive arrangements.
Employee Equity Incentive Program and Workforce Engagement
The exercise of employee options demonstrates Lumos Diagnostics’ use of equity-based compensation to attract, retain, and motivate key personnel. Such schemes are common in diagnostic technology and healthcare sectors. The cashless exercise method, allowing employees to realise value without upfront cash, indicates economic benefit perceived by option holders and possibly reflects share price appreciation relative to exercise prices.
This cashless mechanism is particularly valuable in sectors where employees may have limited capital but benefit from equity incentives tied to company performance. The disclosed exercise activity shows active workforce participation in the equity program, aligning employee interests with shareholder value creation.
Point-of-Care Diagnostics Market Trends and Industry Overview
Lumos Diagnostics operates in the global point-of-care diagnostics market, which is experiencing strong growth due to rising demand for rapid diagnostic capabilities, increasing prevalence of infectious and inflammatory diseases, and technological advances enhancing accuracy and usability. The COVID-19 pandemic accelerated adoption of rapid testing worldwide, sustaining demand for fast, reliable diagnostic solutions across multiple disease categories.
Companies like Lumos Diagnostics that integrate proprietary diagnostic tests with digital reader platforms hold a competitive edge by enabling data capture, quality control, and connectivity features that improve clinical utility. Their combined focus on customised services and proprietary products allows them to serve diverse customers, from healthcare systems seeking integrated solutions to providers requiring specific diagnostics for disease management.
2026 Annual Report Release and Investor Disclosure Timeline
Lumos Diagnostics plans to release its 2026 Annual Report on or before 31 August 2026, complying with ASX listing rules and Corporations Act requirements. The report will include detailed financial statements, management analysis of operational and financial performance for the year ended 30 June 2026, and disclosure of material business matters. The absence of excluded information in the draft report provides investors assurance that the company’s financial condition and trading results have not materially deteriorated since the share issuance.
This disclosure timeline is important for investors and market participants who rely on comprehensive annual reporting to make informed investment decisions. The announcement provides clarity on when detailed financial and strategic information will be available, aiding investor planning.
Governance and Disclosure Committee Oversight
The Section 708A cleansing statement was approved by Lumos Diagnostics’ Disclosure Committee, demonstrating robust governance frameworks for continuous disclosure and regulatory compliance. The committee’s involvement ensures material disclosures are reviewed and authorised by senior management with appropriate authority.
This governance process confirms the accuracy of the announcement and verifies the company’s compliance with continuous disclosure and financial reporting obligations, providing additional assurance to investors and regulators.
Investor Relations and Contact Information
Lumos Diagnostics offers multiple contact points for investors and media seeking further information. Investor relations inquiries can be directed to George Kopsiaftis, Managing Director of IR, at [email protected] or +61 409 392 687. Media inquiries may be addressed to Tom Trezona, H^CK Director, at [email protected] or +61 (0) 411 235 692. The company’s registered office is Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000. General inquiries can be sent to [email protected] or by phone at +61 3 9087 1598.
Providing multiple communication channels underscores Lumos Diagnostics’ commitment to transparency and investor accessibility. Market participants seeking clarification about the share issuance, regulatory compliance, or company strategy are encouraged to contact the company directly.
